ISSN: 1859 - 2872
The clinical and paraclinical characteristics, and treatment outcomes among patients with acute exacerbation of chronic obstructive pulmonary disease with peripheral blood eosinophilia
Main Article Content
Keywords
Abstract
Objective: To describe the clinical and paraclinical characteristics, and treatment outcomes among hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with peripheral blood eosinophilia. Subject and method: This was a retrospective, descriptive study conducted on 227 adult patients (≥18 years old) admitted for AECOPD at the Emergency Department, 108 Military Central Hospital, from 2022 to 2023. Clinical and laboratory parameters, treatments, and outcomes were measured and compared between patients with and without peripheral blood eosinophilia. Result: A total of 227 patients were included and divided into two groups: An eosinophilic group (n = 82, eosinophil ≥ 2%) and a non-eosinophilic group (n = 145, eosinophil < 2%). The eosinophilic group had significantly lower proportion of antibiotic use (p<0.001), non-invasive ventilation (p=0.024), and invasive mechanical ventilation (p=0.035) compared with the non-eosinophilic group. Median hospital length of stay was 7 days in the eosinophilic group versus 9 days in the non-eosinophilic group (p=0.001). There was an inverse correlation between hospital length of stay and peripheral blood eosinophil count. Patients who died during hospitalization had lower eosinophil counts than survivors (p=0.02). Conclusion: Peripheral blood eosinophilia in patients hospitalized for AECOPD may serve as a useful biomarker for risk stratification and prognosis.
Article Details
References
2. Agusti A, Celli BR, Criner GJ et al (2023) Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J 61(4). doi:10.1183/13993003.00239-2023
3. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID (2015) Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 3(6): 435-42. doi:10.1016/S2213-2600(15)00106-X
4. Pavord ID, Lettis S, Locantore N et al (2016) Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax 71(2):118-25. doi:10.1136/thoraxjnl-2015-207021
5. Venkatesan P (2024) GOLD COPD report: 2024 update. Lancet Respir Med 12(1): 15-16. doi:10.1016/s2213-2600(23)00461-7
6. Bafadhel M, McKenna S, Terry S et al (2011) Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 184(6): 662-71. doi:10.1164/rccm.201104-0597OC
7. Prediletto I, Giancotti G, Nava S (2023) COPD Exacerbation: Why It Is Important to Avoid ICU Admission. J Clin Med 12(10)doi:10.3390/jcm12103369
8. Bafadhel M, McKenna S, Terry S et al Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. Jul 1 2012;186(1):48-55. doi:10.1164/rccm.201108-1553OC
9. Donnan M, Liu TL, Gvalda M et al (2025) Clinical Characteristics and Outcomes of Eosinophilic Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 20: 1061-1070. doi: 10.2147/COPD.S485246
10. Duman D, Aksoy E, Agca MC et al (2015) The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int J Chron Obstruct Pulmon Dis 10:2469-78. doi:10.2147/COPD.S90330
11. Rahimi-Rad MH, Asgari B, Hosseinzadeh N, Eishi A (2015) Eosinopenia as a Marker of Outcome in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Maedica (Bucur) 10(1): 10-3.
12. Prudente R, Ferrari R, Mesquita CB et al (2021) Peripheral Blood Eosinophils and Nine Years Mortality in COPD Patients. Int J Chron Obstruct Pulmon Dis. 16: 979-985. doi: 10.2147/COPD.S265275
Article Sidebar
